CJC-1295 vs AICAR
Side-by-Side Comparison
| Attribute | Cjc 1295 | Aicar |
|---|---|---|
| Category | Growth Hormone Secretagogue | Metabolic / Exercise Mimetic |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | AICAR enters cells via adenosine transporters and is phosphorylated by adenosine kinase to ZMP (AICA ribotide), an AMP analog. |
| Evidence Rating | D — Preclinical | C — Early Human or Mixed Evidence |
| Clinical Status | Research-only / Not approved for human use | Phase II/III clinical trials for cardiac ischemia (acadesine). WADA-banned metabolic modulator. No FDA approval. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | In clinical trials (IV acadesine): transient hyperuricemia, mild hypoglycemia at higher doses; Injection site reactions with SC administration |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 1000-5000 mcg per injection |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~258.2 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~1.5-3 hours |
Overview
CJC-1295 and AICAR are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
AICAR — Mechanism & Evidence
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a cell-permeable nucleoside analog (MW ~258.2 g/mol) that is phosphorylated intracellularly to ZMP, which directly activates AMP-activated protein kinase (AMPK). As an exercise mimetic, it triggers many of the same metabolic adaptations as physical exercise — including enhanced glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and improved insulin sensitivity — without requiring muscular contraction. It has been studied in Phase II/III trials for cardiac ischemia and is banned by WADA as a metabolic modulator.
Key claims: Mimics exercise-induced metabolic adaptations; Enhances fatty acid oxidation; Improves insulin sensitivity.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
AICAR is also researched for: Metabolic Health.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
AICAR: In clinical trials (IV acadesine): transient hyperuricemia, mild hypoglycemia at higher doses Injection site reactions with SC administration Theoretical risk of lactic acidosis with excessive AMPK activation
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.